A Smart Sleep Apnea Self-management Support Programme(4S) for Subjects With Sleep Apnea

Sponsor
The University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05390138
Collaborator
(none)
120
2
30.7

Study Details

Study Description

Brief Summary

OSA is a chronic disease with high prevalence that parallels with increasing obesity. Self-management programmes are perceived to be cost-effective in long-term OSA patient care and can supplement regular medical treatments. The current study attempt to examine the effectiveness of 4S on improving apnea severity, cardiovascular health and quality of life in 4S intervention (4S) group, compared to the general hygiene (GH) control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Smart Sleep Apnea Self-management Support Programme (4S)
  • Behavioral: General Hygiene Information (GH)
N/A

Detailed Description

OSA is a chronic disease with high prevalence that parallels with increasing obesity. OSA affects around 12% and 24% of adults in Hong Kong and China Mainland, respectively. Chronic intermittent hypoxia and sleep fragmentation of OSA leads to cardiometabolic and neurocognitive sequelae (e.g. hypertension, diabetes, daytime sleepiness and depression). Long-term, multidisciplinary management involving patients in decision-making of treatment strategies, shifting from positive airway pressure (PAP) device-focused to the patient-centered chronic care model has been suggested.

Mobile instant messaging (such as WhatsApp/WeChat) are popular and inexpensive for interactive messaging. Smartphone-based self-management interventions were reported improved self-efficacy and clinical outcomes in patients with chronic diseases. The investigator only found one mobile health application to support CPAP therapy for OSA and one ongoing trial of OSA self-management telematic support to improve CPAP adherence. There is underutilization of mobile technology in patient-centered self-management programmes to improve PAP treatment and lifestyle modifications in OSA.

The current study attempt to examine the effectiveness of 4S on improving apnea severity, cardiovascular health and quality of life in 4S intervention (4S) group, compared to the general hygiene (GH) control group. Questionnaire and simple fitness assessment will be used to assess the effectivness of the intervention at 4-month and 12-month follow-up. Focus group interview will be conducted to collect qualiatative feedback on the intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a 2-group randomisation controlled trial with 4-month and 12-month follow-up. The Experimental group will receive 4S intervention in relation to self-management and the Control group will receive general hygiene information.This is a 2-group randomisation controlled trial with 4-month and 12-month follow-up. The Experimental group will receive 4S intervention in relation to self-management and the Control group will receive general hygiene information.
Masking:
Single (Outcomes Assessor)
Masking Description:
The outcome assessor did not aware of which groups the patients belongs to.
Primary Purpose:
Supportive Care
Official Title:
A Smart Sleep Apnea Self-management Support Programme(4S) to Improve Apnea Severity and Cardiovascular Health - A Pragmatic Randomized Controlled Trial With Mixed-method Evaluation
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Sep 20, 2024
Anticipated Study Completion Date :
Dec 20, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Smart Sleep Apnea Self-management Support Programme (4S)

Patients will receive Smart Sleep Apnea Self-management Support Programme (4S) in addition to usual care

Behavioral: Smart Sleep Apnea Self-management Support Programme (4S)
The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
Other Names:
  • 4S group
  • Placebo Comparator: General Hygiene Information (GH)

    Patients will receive general hygiene information (GH) in addition to usual care

    Behavioral: General Hygiene Information (GH)
    The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
    Other Names:
  • GH group
  • Outcome Measures

    Primary Outcome Measures

    1. Change in apnea hypopnea index [Baseline, 4 months]

      Apnea hypopnea index will be asssessed by sleep test. The apnea hypopnea index is the number of times of apnea or hypopnea during one night, divided by the hours of sleep. The higher the apnea hypopnea index, the more severe sleep apnea is.

    Secondary Outcome Measures

    1. Change in apnea hypopnea index [Baseline and 12 months]

      Apnea hypopnea index will be assessed by sleep test. The apnea hypopnea index is the number of times of apnea or hypopnea during one night, divided by the hours of sleep. The higher the apnea hypopnea index, the more severe sleep apnea is.

    2. Change in Duration of <90% oxygen desaturation [Baseline, 4 months and 12 months]

      Duration of <90% oxygen desaturation will be assessed by sleep test.

    3. Change in body weight [Baseline, 4 months and 12 months]

      Body weight will be measured.

    4. Change in body fat [Baseline, 4 months and 12 months]

      Body fat will be measured.

    5. Change in body neck circumference [Baseline, 4 months and 12 months]

      Neck circumference will be measured.

    6. Change in waist circumference [Baseline, 4 months and 12 months]

      Waist circumference will be measured.

    7. Change in hip circumference [Baseline, 4 months and 12 months]

      Hip circumference will be measured.

    8. Change objective physical activity level [Baseline, 4 months and 12 months]

      Steps count and acceleration pattern of physical activity will be measured by a 7-day waist-worn accelerometer.

    9. Change in Hand grip strength [Baseline, 4 months and 12 months]

      Hand grip strength will be measured by a dynamometer.

    10. Change in lower limb strength [Baseline, 4 months and 12 months]

      Lower limb strength will be measured by a 30-second chair stand test.

    11. Change in flexibility [Baseline, 4 months and 12 months]

      Flexibility will be measured by a sit and reach test.

    12. Change in balance [Baseline, 4 months and 12 months]

      Balance will be measured by a single-leg stance test.

    13. Change in daytime sleepiness [Baseline, 4 months and 12 months]

      Daytime sleepiness will be measured by a 8-item Epworth Sleepiness Scale with a 3-point Likert scale. Total scores range from 0 to 24. Higher scores reflect greater daytime sleepiness.

    14. Change in sleep quality [Baseline, 4 months and 12 months]

      Sleep quality will be measured by a 7-item Insomnia Severity Index with a 4-point Likert scale. Total scores range from 0 to 28. Higher scores reflect greater severity of insomnia.

    15. Change in functional outcomes of sleep [Baseline, 4 months and 12 months]

      Functional outcomes of sleep will be measured by 10-item Functional Outcomes of Sleep Questionnaire with a 4-point Likert scale. Total scores range from 10 to 40. Higher scores reflect better functional outcomes of sleep.

    16. Change in quality of life [Baseline, 4 months and 12 months]

      Quality of life will be measured by 5-item EuroQol 5-Dimension questionnaire. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    17. Change in anxiety symptoms [Baseline, 4 months and 12 months]

      Anxiety symptoms will be measured by Generalised Anxiety Disorder Assessment (GAD-7) with a 3-point Likert scale. Total scores range from 0 to 21. Higher scores reflect more higher anxiety symptoms.

    18. Change in depressive symptoms [Baseline, 4 months and 12 months]

      Depressive symptoms will be measured by 9-item Patient Health Questionnaire-9 (PHQ-9) with a 3-point Likert scale. Total scores range from 0 to 27. Higher scores reflect more higher depressive symptoms.

    19. Change in subjective happiness [Baseline, 4 months and 12 months]

      Subjective happiness will be measured by 4-item Subjective Happiness Scale with a 7-point Likert scale. Total scores range from 4 to 28. The highest scores reflect greater happiness.

    20. Change in subjective physical activity level [Baseline, 4 months and 12 months]

      Subjective physical activity level will be measured by 8-item International Physical Assessment Questionnaire -short version

    21. Change in dietary habits [Baseline, 4 months and 12 months]

      Dietary habits will be measured by 10-item dietary intake and practice questionnaire.

    22. Change in self-efficacy in CPAP use [Baseline, 4 months and 12 months]

      Self-efficacy in CPAP use will be measured by a 26-item Self-efficacy Measure for Sleep Apnea. Each Item ranges from 1 to 4: Higher scores indicate greater perceived self-efficacy, greater perceived response efficacy, and higher perceived susceptibility.

    23. Change in exercise and dietary control self-efficacy [Baseline, 4 months and 12 months]

      Exercise and dietary control self-efficacy will be measured by outcome-based questionnaire. Each item ranges from 1-10. The higher scores indicate higher self-efficacy

    24. Change in perceived support from family and peers [Baseline, 4 months and 12 months]

      Perceived support from family and peers measured by a 8-item Multidimensional Scale of Perceived Social Support with a 7-point Likert scale. Total scores for both family and peer subscales range from 4 to 28. Higher scores reflect better perceived social support.

    25. Change in patient activation [Baseline, 4 months and 12 months]

      Knowledge, skills and confidence in self-management were measured by a 13-item Patient Activation Measure Scale. The total score ranges from 0 (no activation) to 100 (high activation), with higher scores denoting the better patient activation.

    26. Intervention credibility [4 months and 12 months]

      The rationale of the delivered treatment and its efficacy to alleviate sleep apnea will be measured using the 4-item Credibility of Treatment Rating Scale. Each item ranges from 1-6. The higher scores indicate higher credibility.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • aged 18 years and above;

    • diagnosis of moderate to severe obstructive sleep apnea (AHI≥15);

    • physically inactive (self-reported moderate physical activity per week of <150 minutes);

    • overweight (BMI≥23 kg/m2);

    • mentally, cognitively and physically fit to join the trial as determined by the doctor in-charge and responsible clinical investigators;

    • able to speak and read Chinese;

    • willing to complete the questionnaires and assessments;

    • has a smartphone with instant messaging function (eg. WhatsApp/WeChat); and

    • willing to give informed consent.

    Exclusion Criteria:
    • sleep disorder other than OSA;

    • clinically significant psychiatric, neurological, or medical disorder other than OSA; and

    • use of prescription drugs or clinically significant drugs affecting sleep.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • The University of Hong Kong

    Investigators

    • Principal Investigator: Agnes YK Lai, PhD, The University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr. Agnes Yuen-Kwan Lai, Assistant Professor, The University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT05390138
    Other Study ID Numbers:
    • UW 21-135
    First Posted:
    May 25, 2022
    Last Update Posted:
    May 25, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 25, 2022